AlzeCure Pharma investor relations material
Listen to the latest call from AlzeCure Pharma
AlzeCure Pharma AB (publ), a clinical-stage biopharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease; ACD857, ACD679 and ACD680 for Alzheimer's disease; ACD440 and TrkA-NAM for neuropathic pain; and DBS-10134 (ACD423) for migraine headache.